|
1
|
Human Proteinpedia enables sharing of human protein data.
|
Nat Biotechnol
|
2008
|
4.21
|
|
2
|
Proteomic characterization of the interstitial fluid perfusing the breast tumor microenvironment: a novel resource for biomarker and therapeutic target discovery.
|
Mol Cell Proteomics
|
2004
|
1.57
|
|
3
|
Expression of S100A4 by a variety of cell types present in the tumor microenvironment of human breast cancer.
|
Int J Cancer
|
2007
|
1.53
|
|
4
|
Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions.
|
Mol Cell Proteomics
|
2005
|
1.32
|
|
5
|
Immediate and delayed effects of E-cadherin inhibition on gene regulation and cell motility in human epidermoid carcinoma cells.
|
Mol Cell Biol
|
2005
|
1.15
|
|
6
|
Proteomics in translational cancer research: toward an integrated approach.
|
Cancer Cell
|
2003
|
1.05
|
|
7
|
bc10: A novel human bladder cancer-associated protein with a conserved genomic structure downregulated in invasive cancer.
|
Int J Cancer
|
2002
|
1.01
|
|
8
|
Loss of expression of the adipocyte-type fatty acid-binding protein (A-FABP) is associated with progression of human urothelial carcinomas.
|
Mol Cell Proteomics
|
2005
|
1.00
|
|
9
|
Expression of the tumor suppressor protein 14-3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition.
|
Mol Cell Proteomics
|
2004
|
1.00
|
|
10
|
Molecular characterization of apocrine carcinoma of the breast: validation of an apocrine protein signature in a well-defined cohort.
|
Mol Oncol
|
2009
|
0.99
|
|
11
|
Bladder cancer-associated protein, a potential prognostic biomarker in human bladder cancer.
|
Mol Cell Proteomics
|
2009
|
0.98
|
|
12
|
Omics-based profiling of carcinoma of the breast and matched regional lymph node metastasis.
|
Proteomics
|
2008
|
0.95
|
|
13
|
Proteomic profiling of triple-negative breast carcinomas in combination with a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in estrogen receptor negative breast cancer.
|
Mol Cell Proteomics
|
2012
|
0.91
|
|
14
|
Towards discovery-driven translational research in breast cancer.
|
FEBS J
|
2005
|
0.90
|
|
15
|
Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia.
|
FEBS Lett
|
2006
|
0.89
|
|
16
|
15-prostaglandin dehydrogenase expression alone or in combination with ACSM1 defines a subgroup of the apocrine molecular subtype of breast carcinoma.
|
Mol Cell Proteomics
|
2008
|
0.88
|
|
17
|
Characterization of breast precancerous lesions and myoepithelial hyperplasia in sclerosing adenosis with apocrine metaplasia.
|
Mol Oncol
|
2007
|
0.84
|
|
18
|
Integrating proteomic and functional genomic technologies in discovery-driven translational breast cancer research.
|
Mol Cell Proteomics
|
2003
|
0.84
|
|
19
|
A combined proteome and ultrastructural localization analysis of 14-3-3 proteins in transformed human amnion (AMA) cells: definition of a framework to study isoform-specific differences.
|
Mol Cell Proteomics
|
2008
|
0.84
|
|
20
|
Impact of proteomics on bladder cancer research.
|
Pharmacogenomics
|
2004
|
0.83
|
|
21
|
Proteomic strategies to reveal tumor heterogeneity among urothelial papillomas.
|
Mol Cell Proteomics
|
2002
|
0.82
|
|
22
|
Tissue proteomics of the human mammary gland: towards an abridged definition of the molecular phenotypes underlying epithelial normalcy.
|
Mol Oncol
|
2010
|
0.82
|
|
23
|
Apocrine cysts of the breast: biomarkers, origin, enlargement, and relation with cancer phenotype.
|
Mol Cell Proteomics
|
2005
|
0.79
|
|
24
|
Identification of a subset of breast carcinomas characterized by expression of cytokeratin 15: relationship between CK15+ progenitor/amplified cells and pre-malignant lesions and invasive disease.
|
Mol Oncol
|
2007
|
0.79
|
|
25
|
Immunoexpression analysis and prognostic value of BLCAP in breast cancer.
|
PLoS One
|
2012
|
0.78
|